VERAXA Biotech AG (NASDAQ: VRXA), a developer of next-generation antibody-based cancer therapies, announced the appointment of Raju Willener as chief financial officer, effective immediately. Willener brings more than three decades of international financial leadership experience spanning global capital markets, investment banking, corporate finance, asset management, and strategic leadership. He will report to CEO and Co-Founder Christoph Antz, Ph.D., and is expected to support the company’s capital strategy, strategic opportunities, and continued development of its proprietary BiTAC(R) technology platform and oncology pipeline.
The appointment comes at a critical time for VERAXA as it advances its pipeline of bispecific T cell engagers, bispecific ADCs, and other innovative formats. Willener’s extensive background in corporate finance and capital markets will be instrumental in navigating the complexities of funding clinical development and scaling operations. Prior to joining VERAXA, Willener served as director of corporate development at Exentis Group AG before being appointed CFO in 2025, where he led M&A initiatives, financial strategy, and key corporate functions. Earlier in his career, he held senior executive and investment positions overseeing areas including corporate finance, capital markets, investor relations, and investment portfolios exceeding CHF 30 billion in assets under management.
Willener’s appointment signals VERAXA’s commitment to strengthening its financial leadership as it progresses toward clinical milestones. The company’s BiTAC platform, developed from scientific breakthroughs at the European Molecular Biology Laboratory (EMBL), represents a novel approach to cancer therapy. With Willener’s expertise, VERAXA is better positioned to attract investment, forge strategic partnerships, and manage its resources effectively. His experience in managing large investment portfolios and leading corporate development will be key as VERAXA seeks to maximize the value of its pipeline and technology.
The biotech sector has seen increased volatility in recent years, making strong financial stewardship essential. Companies like VERAXA, with promising platforms but significant capital requirements, need CFOs who can navigate market conditions and secure funding. Willener’s track record in investment banking and asset management suggests he is well-equipped to lead VERAXA’s financial strategy. His role will likely involve not only traditional CFO duties but also active engagement with investors and potential partners. As VERAXA continues to develop its therapies, the appointment of a seasoned financial executive could be a pivotal factor in its success.
For more information on VERAXA Biotech and its latest updates, visit the company’s newsroom at http://nnw.fm/VRXA. The full press release about the CFO appointment is available at https://nnw.fm/jcHOU.
